<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620490</url>
  </required_header>
  <id_info>
    <org_study_id>4068</org_study_id>
    <nct_id>NCT00620490</nct_id>
  </id_info>
  <brief_title>Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy</brief_title>
  <official_title>Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia : Paravertebral Analgesia With a Catheter Associated With Intravenous Morphine Patient-controlled-analgesia (Pca)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      osteolateral thoracotomy is a painful surgical procedure.Thoracic epidural analgesia (TEA) is
      usually considered as the &quot;gold standard&quot; for postoperative thoracic analgesia.
      Unfortunately, it's not always possible to realize it because of contraindications or because
      of technical failures.Analgesia using a paravertebral block is an alternative to the TEA : it
      provides an unilateral sensitive and sympathetic block using a catheter.In our study, the
      catheter will be placed by the thoracic surgeon at the end of the surgical procedure, under
      direct vision, to insure maximal security also on patients on antiplatelets agents,
      anticoagulants or with haemostasis disorders (the placement of the catheter by the
      anaesthetist with the loss of resistance technique is contraindicated in these
      cases).Patients will be randomized to receive either a continuous 48-hours infusion of
      ropivacaine 0,5% or saline serum in the control group.All patients are connected to a PCA
      pump with intravenous morphine and will receive paracetamol and nefopam.The visual analogic
      scale (VAS) at rest and on movement, total morphine consumption and side effects will be
      recorded during the first 48 hours after surgery. The aim of this study is to prove a
      decrease of pain at rest and on movement, a decrease of the cumulated total morphine dose
      consumption and a decrease of the side effects (nausea, vomiting, pruritus, sedation,
      bradypnea, urinary retention).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>first 48 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>· Total dosis of morphine consumption, side effects nausea, vomiting,pruritus,Urinary retention, respiratory rate and sedation, · heart rate, blood pressure and peripheral saturation</measure>
    <time_frame>first 48 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine 0.5% 0.1 ml/kg per hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>Ropivacaine 0.5% 0.1 ml/kg per hour</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nacl 0,9%</intervention_name>
    <description>saline 0.9% 0.1 ml/kg per hour</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for thoracotomy who presented with contraindications to
             TEA.Contraindications to TEA are :

          -  Patient's refusal after informations about advantages and risks of the technique

          -  Anti platelets treatment that can't be discontinued

          -  Anticoagulants at a curative dosage- haemostasis and/or coagulation disorders:
             thrombopenia &lt; 100.000/mm3, ACT &gt; 1,5 / control, PTT &lt; 75%- Systemic or local
             infection of the puncture point

          -  2 and 3 grade atrio-ventricular heart block without pacing

          -  Severe aortic valve stenosis

          -  Kyphoscoliosis

          -  certain neurological disorders

        Exclusion Criteria:

          -  Patient's refusal to participate in the study

          -  Psychiatric disorder (impossibility to collect the informed consent)

          -  Patient under juridical protection

          -  On going an other study

          -  Pregnancy, breastfeeding

          -  Non balanced epilepsy

          -  3 grade auriculae-ventricular heart block without pacing

          -  Severe hepatocellular insufficiency

          -  Anti arrhythmic treatment : class III of the Vaughan William's classification- Skin
             infection of the puncture point

          -  Allergy to aminoamides local anaesthetic

          -  Surgical difficulties to insert paravertebral catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Helms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Thoracique, Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Emmanuel Lavoué, Directeur adjoint de la recherche clinique et de l'innovation</name_title>
    <organization>Hôpitaux Universitaires de Strasbourg</organization>
  </responsible_party>
  <keyword>Epidural analgesia</keyword>
  <keyword>Contraindications</keyword>
  <keyword>Paravertebral nerve block analgesia</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>Visual analogical scale</keyword>
  <keyword>Morphine</keyword>
  <keyword>Side effects</keyword>
  <keyword>Pain and thoracotomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

